Evidence map›Paper›PMID 35600349›Full record

ReviewFrontiers in oncology2022

Predictive Biomarkers in Thyroid Cancer.

Elisabetta Macerola, Anello Marcello Poma, Paola Vignali, Agnese Proietti, Clara Ugolini, Liborio Torregrossa, Alessio Basolo, Rossella Elisei, Ferruccio Santini, Fulvio Basolo

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Is Melanoma Progression Affected by Thyroid Diseases?International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Elisabetta MacerolaDepartment of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Anello Marcello PomaDepartment of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Paola VignaliDepartment of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Agnese ProiettiDepartment of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Clara UgoliniDepartment of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Liborio TorregrossaDepartment of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Alessio BasoloDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Rossella EliseiDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Ferruccio SantiniDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Fulvio BasoloDepartment of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
University of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In molecular pathology, predictive biomarkers identify which patients are likely to respond to targeted drugs. These therapeutic agents block specific molecules directly involved in cancer growth, dedifferentiation and progression. Until few years ago, the only targeted drugs available for advanced thyroid cancer included multi-tyrosine kinase inhibitors, mainly targeting the MAPK pathway and the angiogenic signaling. The administration of these drugs does not necessarily require a molecular characterization of tumors to assess the presence of predictive alterations. However, the availability of new selective targeted drugs for thyroid cancer patients is changing the diagnostic strategies for the molecular characterization of these tumors. The search for targetable alterations can be performed directly on tumor tissue by using a variety of methodologies, depending also on the number and type of alterations to test (i.e. single nucleotide variation or gene rearrangement). Herein, a comprehensive review of the currently available targeted treatments for thyroid cancer, related predictive markers and testing methodologies is provided.

Indexed as

molecular markermolecular pathologypredictive markertargeted therapythyroid cancer

Identifiers

PMID35600349
PMCPMC9120826
OpenAlexW4229015125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.